問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Chi Mei Hospital, Liouying (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Urology

Chi Mei Medical Center

更新時間：2023-09-19

曹朝榮
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

119Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曹朝榮

List

237Cases

2006-01-01 - 2008-01-01

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

2022-09-01 - 2024-07-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting2Sites

Terminated4Sites

2017-02-10 - 2025-12-31

Phase III

A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti PD 1 Antibody) versus Platinum Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic PD L1 + Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN2810

Participate Sites
17Sites

Recruiting13Sites

Terminated2Sites

夏德椿
China Medical University Hospital-Taipei

未分科

張家崙
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Hematology & Oncology

2019-04-01 - 2025-06-30

Phase II

A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
8Sites

Recruiting8Sites

2009-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-09-01 - 2017-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-09-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Suspended3Sites

2005-12-01 - 2007-11-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2014-03-15 - 2017-12-31

Phase II

A PHASE 2, RANDOMIZED, OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACODYNAMICS, PHARMACOKINETICS OF THE ANTI-ALK-1 MAB PF-03446962 IN COMBINATION WITH BEST SUPPORTIVE CARE VS. BEST SUPPORTIVE CARE ALONE IN ADULT PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    PF-03446962 injection

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2006-11-20 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

1 20 21 22 23 24
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB